Anand Sampath's most recent trade in Masimo Corp was a trade of 2,637 Non-Qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 26, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Masimo Corp | Anand Sampath | EVP, Ops & Clinical Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 2,637 | 2,637 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Masimo Corp | Anand Sampath | EVP, Ops & Clinical Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 14,593 | 29,589 (0%) | 0% | 0 | Common Stock | |
| Masimo Corp | Anand Sampath | EVP, Ops & Clinical Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 2,000 | 15,782 (0%) | 0% | 0 | Common Stock | |
| Masimo Corp | Anand Sampath | EVP, Ops & Clinical Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2021 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Masimo Corp | Anand Sampath | EVP, Ops & Clinical Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 268.38 per share. | 02 Jan 2021 | 786 | 14,996 (0%) | 0% | 268.4 | 210,947 | Common Stock |